Featured Research

from universities, journals, and other organizations

Idiopathic pulmonary fibrosis: Promising drug therapies for fatal lung disease found

Date:
May 19, 2014
Source:
Cedars-Sinai Medical Center
Summary:
Two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, researchers in separate clinical trials found. The senior author of the multicenter study that found that the investigational drug pirfenidone significantly slowed the loss of lung function and reduced the risk of death.

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

Paul W. Noble, MD, chair of the Department of Medicine at Cedars-Sinai and director of the Women's Guild Lung Institute, is the senior author of the multicenter study that found that the investigational drug pirfenidone significantly slowed the loss of lung function and reduced the risk of death. Pirfenidone was developed by InterMune Inc. and in 2011 was approved by the European Union for the treatment of idiopathic pulmonary fibrosis.

The findings of the ASCEND drug trial are published online by the New England Journal of Medicine and are being presented this week at the International Conference of the American Thoracic Society in San Diego. "What we discovered about the anti-inflammatory and anti-fibrotic properties of pirfenidone offers help and encouragement to so many patients suffering from this relentless disease that robs them of breath and life," said Noble.

Idiopathic pulmonary fibrosis causes the regions of the lungs where oxygen gets to the blood to thicken and scar, leaving patients with shortness of breath, a chronic cough and extreme fatigue. Most patients die within two to five years of diagnosis.

"Not only did pirfenidone prevent the loss of lung function and preserve the distance patients could walk, but during the study the risk of death was reduced by a remarkable 48 percent in those taking the drug when compared with those who received placebo," said Noble." The findings were so strong that an early access program has been initiated to provide patients with pirfenidone while the process of obtaining FDA approval is undertaken. Cedars-Sinai will be participating in this program under the direction of Dr. Jeremy Falk and the Advanced Lung Disease Program.

Noble also was a co-author of a second study testing the efficacy and safety of the multi-kinase inhibitor nintedanib on idiopathic pulmonary fibrosis patients. Nintedanib is also is being studied in lung cancer.

"In our research we found that nintedanib could also slow the loss of lung function in patients with idiopathic pulmonary fibrosis," said Noble. "It is a second dose of good news for our patients because nintedanib not only slowed the progression of the disease, but it tended to reduce acute exacerbations of the disease, while tending to preserve the quality of life of the study patients receiving the drug."

Noble is a paid consultant of InterMune Inc. and Boehringer-Ingelheim for his work on the steering committees of the two clinical trials. Cedars--Sinai was not among the medical centers participating in this multicenter study of the drug's efficacy in treating idiopathic pulmonary fibrosis.

"These IPF drug therapy findings by Dr. Noble and his colleagues exemplify the dedication and hard work required to find treatments for a group of patients who have so few therapeutic options because there have been no drugs approved by the Food and Drug Administration specifically targeted for treating this fatal disease," said Shlomo Melmed, MD, senior vice president and dean at Cedars-Sinai and the Helene A. and Philip E. Hixon Chair in Investigative Medicine.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, Eduard Gorina, Peter M. Hopkins, David Kardatzke, Lisa Lancaster, David J. Lederer, Steven D. Nathan, Carlos A. Pereira, Steven A. Sahn, Robert Sussman, Jeffrey J. Swigris, Paul W. Noble. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014; 140518140014004 DOI: 10.1056/NEJMoa1402582

Cite This Page:

Cedars-Sinai Medical Center. "Idiopathic pulmonary fibrosis: Promising drug therapies for fatal lung disease found." ScienceDaily. ScienceDaily, 19 May 2014. <www.sciencedaily.com/releases/2014/05/140519110322.htm>.
Cedars-Sinai Medical Center. (2014, May 19). Idiopathic pulmonary fibrosis: Promising drug therapies for fatal lung disease found. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2014/05/140519110322.htm
Cedars-Sinai Medical Center. "Idiopathic pulmonary fibrosis: Promising drug therapies for fatal lung disease found." ScienceDaily. www.sciencedaily.com/releases/2014/05/140519110322.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins